Insights from the Global Longitudinal Study of Osteoporosis in Women (GLOW)
UMass Chan Affiliations
Center for Outcomes ResearchDocument Type
Journal ArticlePublication Date
2014-07-01Keywords
Accidental FallsAged
Aged, 80 and over
Comorbidity
Female
Hip Fractures
Hospitalization
Humans
Longitudinal Studies
Middle Aged
Obesity
Osteoporosis
Osteoporosis, Postmenopausal
Osteoporotic Fractures
Prevalence
Quality of Life
Risk
Risk Factors
Spinal Fractures
Endocrinology, Diabetes, and Metabolism
Epidemiology
Health Services Research
Musculoskeletal Diseases
Women's Health
Metadata
Show full item recordAbstract
GLOW is an observational, longitudinal, practice-based cohort study of osteoporosis in 60,393 women aged ≥ 55 years in 10 countries on three continents. In this Review, we present insights from the first 3 years of the study. Despite cost analyses being frequently based on spine and hip fractures, we found that nonvertebral, nonhip fractures were around five times more common and doubled the use of health-care resources compared with hip and spine fractures combined. Fractures not at the four so-called major sites in FRAX(®) (upper arm, forearm, hip and clinical vertebral fractures) account for > 40% of all fractures. The risk of fracture is increased by various comorbidities, such as Parkinson disease, multiple sclerosis and lung and heart disease. Obesity, although thought to be protective against all fractures, substantially increased the risk of fractures in the ankle or lower leg. Simple assessment by age plus fracture history has good predictive value for all fractures, but risk profiles differ for first and subsequent fractures. Fractures diminish quality of life as much or more than diabetes mellitus, arthritis and lung disease, yet women substantially underestimate their own fracture risk. Treatment rates in patients at high risk of fracture are below those recommended but might be too frequent in women at low risk. Comorbidities and the limits of current therapeutic regimens jeopardize the efficacy of drugs; new regimens should be explored for severe cases.Source
Watts NB; GLOW investigators. Insights from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Nat Rev Endocrinol. 2014 Jul;10(7):412-22. doi:10.1038/nrendo.2014.55. Epub 2014 Apr 22. Review. PubMed PMID: 24751880. Link to article on publisher's websiteDOI
10.1038/nrendo.2014.55Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27159PubMed ID
24751880Related Resources
Link to article in PubMedae974a485f413a2113503eed53cd6c53
10.1038/nrendo.2014.55